DK1149090T3 - Ny krystallinsk form af kaliumsalt af (S)-omeprazol - Google Patents

Ny krystallinsk form af kaliumsalt af (S)-omeprazol

Info

Publication number
DK1149090T3
DK1149090T3 DK00903058T DK00903058T DK1149090T3 DK 1149090 T3 DK1149090 T3 DK 1149090T3 DK 00903058 T DK00903058 T DK 00903058T DK 00903058 T DK00903058 T DK 00903058T DK 1149090 T3 DK1149090 T3 DK 1149090T3
Authority
DK
Denmark
Prior art keywords
omeprazole
crystalline form
potassium salt
new crystalline
new
Prior art date
Application number
DK00903058T
Other languages
Danish (da)
English (en)
Inventor
Maths Nilsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1149090T3 publication Critical patent/DK1149090T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK00903058T 1999-01-28 2000-01-18 Ny krystallinsk form af kaliumsalt af (S)-omeprazol DK1149090T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900274A SE9900274D0 (sv) 1999-01-28 1999-01-28 New compound
PCT/SE2000/000087 WO2000044744A1 (en) 1999-01-28 2000-01-18 Potassium salt of ($i(s))-omeprazole

Publications (1)

Publication Number Publication Date
DK1149090T3 true DK1149090T3 (da) 2003-06-30

Family

ID=20414267

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00903058T DK1149090T3 (da) 1999-01-28 2000-01-18 Ny krystallinsk form af kaliumsalt af (S)-omeprazol

Country Status (40)

Country Link
US (1) US6511996B1 (ru)
EP (1) EP1149090B1 (ru)
JP (1) JP2002535401A (ru)
KR (1) KR100624054B1 (ru)
CN (1) CN1231477C (ru)
AR (1) AR022425A1 (ru)
AT (1) ATE236899T1 (ru)
AU (1) AU768676B2 (ru)
BG (1) BG65060B1 (ru)
BR (1) BR0007647A (ru)
CA (1) CA2357744C (ru)
CZ (1) CZ300504B6 (ru)
DE (1) DE60002042T2 (ru)
DK (1) DK1149090T3 (ru)
DZ (1) DZ3001A1 (ru)
EE (1) EE04240B1 (ru)
EG (1) EG23980A (ru)
ES (1) ES2193937T3 (ru)
HK (1) HK1041259B (ru)
HU (1) HU226766B1 (ru)
ID (1) ID30095A (ru)
IL (1) IL144107A0 (ru)
IS (1) IS2019B (ru)
MY (1) MY119095A (ru)
NO (1) NO319719B1 (ru)
NZ (1) NZ512804A (ru)
PL (1) PL197881B1 (ru)
PT (1) PT1149090E (ru)
RS (1) RS50200B (ru)
RU (1) RU2237666C2 (ru)
SA (1) SA00200895B1 (ru)
SE (1) SE9900274D0 (ru)
SI (1) SI1149090T1 (ru)
SK (1) SK285626B6 (ru)
TN (1) TNSN00017A1 (ru)
TR (1) TR200102138T2 (ru)
TW (1) TWI269795B (ru)
UA (1) UA71594C2 (ru)
WO (1) WO2000044744A1 (ru)
ZA (1) ZA200105526B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
EP1633736A1 (en) 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
KR20130038949A (ko) * 2004-06-24 2013-04-18 아스트라제네카 아베 에소메프라졸 나트륨염의 제조에서 사용하기 위한 결정 변형의 제조를 위한 신규한 방법
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US20100286208A1 (en) * 2006-06-21 2010-11-11 Bobba Venkata Siva Kumar Novel polymorph of esomeprazole potassium and process for its preparation
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
SI2510089T1 (sl) 2009-12-08 2015-12-31 Codexis, Inc. Sinteza prazolnih spojin
CN102319223B (zh) * 2011-09-21 2013-06-19 石药集团欧意药业有限公司 一种埃索美拉唑冻干制剂及其制备方法
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
BR9506018A (pt) 1994-07-08 1997-09-02 Astra Ab Forma farmacêutica oral de múltipla dosagem unitária em tablete processos para a preparação da mesma para a inibição da secreção de ácido gástrico em mamiferos e no homem e para o tratamento das doenças inflamatórias gastrointestinais em mamiferos e no homem e embalagem de ampola de pressão transversal
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B

Also Published As

Publication number Publication date
ID30095A (id) 2001-11-01
KR100624054B1 (ko) 2006-09-18
KR20010101699A (ko) 2001-11-14
IS2019B (is) 2005-06-15
CA2357744A1 (en) 2000-08-03
MY119095A (en) 2005-03-31
ATE236899T1 (de) 2003-04-15
CZ300504B6 (cs) 2009-06-03
TNSN00017A1 (fr) 2005-11-10
CN1231477C (zh) 2005-12-14
HK1041259A1 (en) 2002-07-05
NZ512804A (en) 2003-07-25
YU53801A (sh) 2004-07-15
HUP0105313A3 (en) 2003-01-28
HK1041259B (zh) 2003-10-24
EE200100395A (et) 2002-10-15
IL144107A0 (en) 2002-05-23
BG105841A (en) 2002-04-30
DE60002042T2 (de) 2003-12-18
BR0007647A (pt) 2001-10-16
SI1149090T1 (en) 2003-10-31
HUP0105313A2 (hu) 2002-05-29
EP1149090A1 (en) 2001-10-31
AU768676B2 (en) 2003-12-18
EE04240B1 (et) 2004-02-16
HU226766B1 (en) 2009-09-28
SK10372001A3 (sk) 2002-02-05
PL197881B1 (pl) 2008-05-30
AR022425A1 (es) 2002-09-04
SA00200895B1 (ar) 2006-11-11
SE9900274D0 (sv) 1999-01-28
NO20013665L (no) 2001-07-26
TWI269795B (en) 2007-01-01
US6511996B1 (en) 2003-01-28
PT1149090E (pt) 2003-07-31
EG23980A (en) 2008-02-27
DE60002042D1 (de) 2003-05-15
CA2357744C (en) 2009-06-16
SK285626B6 (sk) 2007-05-03
NO319719B1 (no) 2005-09-05
NO20013665D0 (no) 2001-07-26
JP2002535401A (ja) 2002-10-22
RS50200B (sr) 2009-07-15
CN1339034A (zh) 2002-03-06
AU2469400A (en) 2000-08-18
EP1149090B1 (en) 2003-04-09
ES2193937T3 (es) 2003-11-16
WO2000044744A1 (en) 2000-08-03
IS5989A (is) 2001-07-05
UA71594C2 (ru) 2004-12-15
DZ3001A1 (fr) 2004-03-27
ZA200105526B (en) 2002-10-04
TR200102138T2 (tr) 2001-12-21
BG65060B1 (bg) 2007-01-31
RU2237666C2 (ru) 2004-10-10
CZ20012730A3 (cs) 2002-02-13

Similar Documents

Publication Publication Date Title
DK1149090T3 (da) Ny krystallinsk form af kaliumsalt af (S)-omeprazol
DK0991641T3 (da) Krystallinsk form af omeprazol-natriumsalt
IS7007A (is) Kristallaform af asiþrómýsíni
IS5640A (is) Ný kristalla form af Bensímídazól efnasambandi gegn veirum
DK1126826T3 (da) Multipartikel-modificeret-frigivelsessammensætning af methylphenidat
DK1077943T3 (da) Heterocykliske inhibitorer af p38
DK1451192T3 (da) Ny krystallinsk forbindelse
DK1360169T3 (da) Succinatsalt af O-desmethyl-venlafaxin
DK1438306T3 (da) Derivater af UK-2A
DK1107980T3 (da) Krystallinske former af EtO2C-CH2-(R)Cgl-Aze-Pab-OH
DK1280803T3 (da) Krystallinsk form II af cabergolin
DK1196431T3 (da) En i det væsentlige krystallinsk form af melagatran
DK1155050T3 (da) Fremstilling af polyolefin
IS5821A (is) Kristalluð form af ósanetant
EE200100381A (et) Morfolinobensamiidi uued soolad
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
DK1088010T3 (da) Fremstilling af polyolefiner
DK1140984T3 (da) Selektive inhibitorer af MMP-12
NO20004583D0 (no) Krystallinsk form av paroxetine
PT1020132E (pt) Aba de puxar destacavel
DK1191025T3 (da) Krystaller af lansoprazol
DK1569695T3 (da) Antisense-modulering af apolipoprotein-b-ekspression
ATE414059T1 (de) Kristalline form des natriumsalzes von 5-chlor-2- methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid
DK1031262T3 (da) Forbedring af rotorharve
SE9904417D0 (sv) Crystalline form